FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-02

Price

$14.36

-0.07%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

FOLD is currently trading as a low-beta Merger Arbitrage play following its December 2025 definitive agreement to be acquired by BioMarin Therapeutics (BMRN) for $14.50 per share. The current price of $14.36 reflects a tight ~1% spread ahead of the expected Q2 2026 closing, which explains the 'Steady Climb' and 'Quiet Storm' signals: volatility has collapsed as the price is pegged to the deal terms. In the current 'Risk-Off' geopolitical regime, FOLD is outperforming the SPY not due to speculative buying, but because it acts as a defensive, uncorrelated asset with a hard floor at the acquisition price, effectively decoupling it from the broader market's stagflationary fears.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

**Thesis:** Pure Merger Arbitrage. The stock is tethered to the $14.50 cash acquisition price; the 14-cent spread represents the time value of money vs. the 4.04% 10Y yield until the Q2 close.
**Signal Confirmation:** The 'Alpha Male' relative strength is a false positive for growth—it is actually 'capital preservation' strength as investors hide in the deal certainty amidst the Iran/Israel escalation.
**Risk:** Deal breakage is the only material risk, but with FTC early termination already granted (per Feb reports), regulatory risk is minimal; the primary risk is an unforeseen 'force majeure' event.

← Back to 2026-03-02 View Full FOLD History →Yahoo Finance &nearr;